Explore how cfDNA levels change around colorectal cancer surgery and their potential as non-invasive biomarkers for ...

The methylation of plasma cell-free DNA (cfDNA) has emerged as a valuable diagnostic and prognostic biomarker in various cancers including colorectal cancer (CRC). Currently, there are no biomarkers ...

Real-world genomic testing performance in colorectal cancer (CRC): The MultiTEAM Systems Framework Precision ... 70% 47% 0.2 Did your care providers talk to you about biomarker testing after your ...

Since Henry Bence Jones first discovered a urine protein marker for multiple myeloma in 1846, the field of cancer biomarkers has grown exponentially. Over the past two centuries, scientists have ...

Pan-cancer microsatellite instability testing using a multiplex assay including long mononucleotide repeats. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium.

By studying biomarkers known to be involved in gastrointestinal cancers, researchers at the Johns Hopkins Kimmel Cancer ...

Pfizer only picked up an accelerated approval from the FDA for its Braftovi-based combination regimen for colorectal cancer ...

Old drugs from Bristol Myers Squibb and Pfizer have delivered what the companies and researchers believe could establish them ...

Aspirin use in patients with PI3K-mutated colorectal cancer helped to reduce disease recurrence, highlighting the importance ...

Taken together, our results suggest that in addition to physiological age, comorbidities and unfavorable clinical traits, ...

A new research paper was published in Oncotarget's Volume 16 on January 21, 2025, titled "Assessment of cfDNA release dynamics during colorectal cancer surgery." ...

Three-year results from the ALASCCA trial (NCT02647099), presented at the 2025 ASCO Gastrointestinal Cancer Symposium, showed ...